| RELATED-PARTY-TENANT |
RELATED-PARTY-TENANT |
90%
|
For the six months ended January 31, 2026 one related-party tenant represented 13 % of the Company’s total revenue. |
| THIRD-PARTY-CUSTOMER |
THIRD-PARTY-CUSTOMER |
90%
|
For the six months ended January 31, 2026 two third-party customers represented 33 % and 13 % of the Company’s total revenue. |
| THIRD-PARTY-TENANT |
THIRD-PARTY-TENANT |
90%
|
For the six months ended January 31, 2026 one third-party tenant represented 25 % of the Company’s total revenue. |
| CORNERSTONE |
CORNERSTONE |
80%
|
Cornerstone received negative results of its Avenger 500 Phase 3 study for Devimistat in pancreatic cancer |
| IDT |
IDT Corporation |
72%
|
y concluded that in accordance with ASC 350 and ASC 360, a triggering event occurred during November 2024, which required the Company to assess if goodwill or long-lived assets were impaired. In acco… |
| IDT |
IDT Corporation |
72%
|
Reciprocal relationship from IDT graph: Reciprocal relationship from RFL graph: y concluded that in accordance with ASC 350 and ASC 360, a triggering event occurred during November 2024, which requir… |
| BARER-INSTITUTE-INC |
BARER-INSTITUTE-INC |
62%
|
ted for under the equity method. RP Finance is an entity associated with members of the family of Howard Jonas (Executive Chairman, Chairman of the Board, and controlling stockholder of the Company) … |
| BROAD-ATLANTIC-ASSOCIATES-LLC |
BROAD-ATLANTIC-ASSOCIATES-LLC |
62%
|
d determined that it was not the primary beneficiary as the Company did not have the power to direct the activities of Cornerstone that most significantly impact Cornerstone’s economic performance. S… |
| CALITHERA-BIOSCIENCES-INC |
CALITHERA-BIOSCIENCES-INC |
62%
|
would have been achieved if the Cornerstone Restructuring, the Cornerstone Acquisition, and RP Finance Consolidation had taken place on the date noted above, or of results that may occur in the futur… |
| CANCER-RESEARCH-LTD |
CANCER-RESEARCH-LTD |
62%
|
United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process … |
| CONSULTING-LLC |
CONSULTING-LLC |
62%
|
United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process … |
| CS-PHARMA-HOLDINGS-LLC |
CS-PHARMA-HOLDINGS-LLC |
62%
|
would have been achieved if the Cornerstone Restructuring, the Cornerstone Acquisition, and RP Finance Consolidation had taken place on the date noted above, or of results that may occur in the futur… |
| CYCLO-THERAPEUTICS-INC |
CYCLO-THERAPEUTICS-INC |
62%
|
22, Broad Atlantic completed the sale of the 520 Property for an aggregate gross purchase price of $ 49.4 million. The 520 Property was encumbered by a mortgage securing a $ 15 million note payable w… |
| CYCLO-THERAPEUTICS-LLC |
CYCLO-THERAPEUTICS-LLC |
62%
|
the Company elected the fair value option to account for its investment in Cyclo, as the Company had significant influence over Cyclo’s management. The fair value option is irrevocable once elected. … |
| FARBER-PARTNERS-LLC |
FARBER-PARTNERS-LLC |
62%
|
United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process … |
| GENIE-ENERGY-LTD |
GENIE-ENERGY-LTD |
62%
|
United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process … |
| IDT-R-E-HOLDINGS-LTD |
IDT-R-E-HOLDINGS-LTD |
62%
|
ted for under the equity method. RP Finance is an entity associated with members of the family of Howard Jonas (Executive Chairman, Chairman of the Board, and controlling stockholder of the Company) … |
| NINA-MEDICAL-LTD |
NINA-MEDICAL-LTD |
62%
|
. Investments without readily determinable fair values are accounted for using the measurement alternative which is at cost minus impairment, if any, plus or minus changes resulting from observable p… |
| PHARMA-HOLDINGS |
PHARMA-HOLDINGS |
62%
|
urity was classified as available-for-sale prior to the Cornerstone Restructuring; (d) a $ 720 thousand receivable balance due from Cornerstone, which was fully reserved for by the Company due to the… |
| PHARMA-HOLDINGS-LLC |
PHARMA-HOLDINGS-LLC |
62%
|
would have been achieved if the Cornerstone Restructuring, the Cornerstone Acquisition, and RP Finance Consolidation had taken place on the date noted above, or of results that may occur in the futur… |
| RP-FINANCE-LLC |
RP-FINANCE-LLC |
62%
|
t are experts in cancer metabolism, chemistry, and drug development. In addition to its own internal discovery efforts, Barer pursued collaborative research agreements and in-licensing opportunities … |
| SHAARE-ZEDEK-SCIENTIFIC-COMPANY |
SHAARE-ZEDEK-SCIENTIFIC-COMPANY |
62%
|
United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process … |
